Skip to main content

Coronavirus: Medical Treatments

Question for Department of Health and Social Care

UIN 18857, tabled on 15 June 2022

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the role of covid-19 antivirals in reducing pressures on the NHS.

Answered on

23 June 2022

No specific assessment has been made. However, clinical trial results indicate that the dual oral antiviral nirmatrelvir/ritonavir resulted in a relative risk reduction of hospitalisation or death by 88% within five days of symptom onset, compared to placebo in non-hospitalised, high-risk adults with COVID-19. Further results show that the oral antiviral molnupiravir administered within five days of symptom onset to high-risk, non-hospitalised patients resulted in a relative risk reduction of 30% in the composite primary outcome of hospitalisation or death at day 29.

Interests declared
The Member has declared that they have interests which may be relevant to the subject matter of this question.